Month: August 2021

NFI New Flyer Xcelsior AVNFI New Flyer Xcelsior AV transit busWINNIPEG, Manitoba, Aug. 12, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in mobility solutions, today announced an agreement with Robotic Research, LLC (“Robotic Research”) to increase the deployment of advanced driver-assistance systems (“ADAS”) in transit agency fleets across North America. The agreement expands the partnership between New Flyer of America Inc. (“New Flyer”, an NFI subsidiary) and Robotic Research originally announced in 2019, and builds on the unveiling of North America’s first automated transit bus, the Xcelsior AV™, to pursue integration of Robotic Research’s AutoDrive® technology into new and existing public transit vehicles....

TORONTO and CHICAGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that is has completed enrollment in its Phase 4 Clinical Trial of IXINITY®, targeting label expansion for pediatric hemophilia B patients. The Trial is investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX. IXINITY® is currently an FDA approved intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B. Medexus has now enrolled its last patient in this Phase 4 Clinical Trial, with the trial expected to be complete in June 2022. On completion, the Company believes this study may support...

Record Sales of $5.5 million, Record Net Earnings of $1.5 million MISSISSAUGA, Ontario, Aug. 12, 2021 (GLOBE NEWSWIRE) —  Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its third quarter and nine months of fiscal 2021 ending June 30, 2021 (“Q3” and “YTD”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from innovative, proprietary, and branded medical devices. Management Discussion Q3 revenues were up 88% from 2020, achieving a record level of $5.45 million as Microbix continues to emphasize operational excellence and the sale of innovative, proprietary, and branded medical devices. Sales of its test quality assessment products (“QAPs™”) for Q3 increased 84% from the same period in fiscal...

TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today announced that it had accepted a Part 36 settlement offer made by Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB. On June 18, 2020, Acerus announced it had commenced litigation against Recipharm in the Commercial Court of London. Acerus alleged that the suspension of Recipharm’s manufacturing license in August 2018 was a violation of its contractual obligations and led to a shortage of Estrace® in Canada. On June 15, 2021, the Company won at a preliminary issue trial in which Recipharm argued unsuccessfully that Acerus’ claim for damages was barred by the terms of the companies’ manufacturing contract. In agreeing with Acerus that its claim for damages was not barred,...

Financial HighlightsQ2 revenue up 29.0%; 26.2% in constant currency Q2 operating earnings of $13.7 million; up 24.1% from a year ago Q2 earnings per share of $0.60 down from $1.04 a year ago; adjusted EPS of $0.49 compared to $0.51TROY, Mich., Aug. 12, 2021 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA) (Nasdaq: KELYB), a leading specialty talent solutions provider, today announced results for the second quarter of 2021. Peter Quigley, president and chief executive officer, announced revenue for the second quarter of 2021 totaled $1.3 billion, a 29.0% increase compared to the corresponding quarter of 2020. Revenue improved year-over-year in the quarter reflecting increased customer demand compared to the COVID-19-impacted prior year period. Earnings from operations in the second quarter of 2021 totaled $13.7 million, compared to...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORDISSEMINATION IN UNITED STATES Inaugural ESG Report ReleasedReconfigured LNG Options Being Considered Key Highlights:Natural gas production of 194 mmcf/day in the quarter Total production of 38,404 boe/day Petroleum and natural gas revenue of $71.4 million, an increase of $17.1 million or 32% compared to the same quarter in 2020 Cash flow from operations of $12.1 million Net Operating Income1 (“NOI”) of $14.4 million and Adjusted Funds Flow From Operations1 (“AFFO”) of $8.5 million Delivered our inaugural ESG report in late June 2021, anchored by our commitment of net zero emissions by 2050 On July 26, 2021, the company announced it had initiated a formal process to identify, examine and consider a range of strategic alternatives with a view to enhancing shareholder valueCALGARY,...

Figure 1Midland-BHP Alliance NunavikFigure 2A1 ProspectFigure 3L2 prospectFigure 4Bonne Une ProspectMONTREAL, Aug. 12, 2021 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to provide an update on a major exploration program underway for nickel in Nunavik. The 2021 program is carried out under the strategic alliance (the “Alliance”) concluded in August 2020 between Midland’s wholly owned subsidiary, Midland Base Metals Inc. (“MBM”), and Rio Algom Limited, wholly owned subsidiary of BHP Group PLC (“BHP”). Highlights:High-quality ground electromagnetic (“Squid”) survey conducted on the Papavoine Ni-Cu-Co prospect. 3D modelling of the Papavoine prospect underway, integrating new ground geophysics and historical drilling data to identify...

– Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – – Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 Expected to Commence in 3Q21 – – Dose Escalation Portion of Phase 1 Trials of Oral and IV Formulations of MCL1 Inhibitor PRT1419 Ongoing –                   -Strong Cash Position of $343 Million to Support Clinical and Discovery Pipeline Advancement – WILMINGTON, Del., Aug. 12, 2021 (GLOBE NEWSWIRE) — Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent clinical and development pipeline progress. “Prelude’s second...

TORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2021. ProMIS Neurosciences is applying its patented technology platform to build a portfolio of antibody therapies, therapeutic vaccines, and diagnostics in neurodegenerative diseases, including Alzheimer’s disease (AD) and other dementias, Parkinson’s Disease (PD), and amyotrophic lateral sclerosis (ALS). These diseases share a common biologic cause – misfolded versions of proteins, that otherwise perform a normal function,...

– Completed upsized $255.6 million IPO; cash runway extended into late 2024 – Continued advancement of QuEEN™ protein degradation platform and pipeline of molecular glue degraders, including NEK7 program – BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today reported business highlights and financial results for the second quarter, ended June 30, 2021. “Following our successful initial public offering and with several pivotal additions to our leadership team, we are excited to have the resources in place to advance our pipeline of novel molecular glues towards and into the clinic and to continue the development of our unique and proprietary QuEEN platform. We are delighted by the continuing progress of our pipeline...